GlobalData on MSN1d
Gilead and MSD to advance once-weekly HIV treatment to Phase III
The companies have presented positive Phase II data during an oral session at IDWeek 2024, in Los Angeles, US.
Success of long-lasting HIV drug hinges on pricing
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
News Medical2d
Affordability and supply remain critical to the success of long-lasting HIV drug
Affordability and mass distribution will be critical to the success of a long-lasting injectable HIV prevention drug that has ...
Zacks.com on MSN2d
Gilead, MRK Report Data From Investigational Combination Study for HIV
Gilead Sciences, Inc. GILD and partner Merck MRK announced new results from a mid-stage study evaluating the investigational ...
News242d
Talks have started to get the twice-yearly anti-HIV jab registered in SA
Gilead Sciences, the maker of a twice-a-year anti-HIV injection, has approached South Africa’s medicine regulator to discuss ...
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable ...
Kidney transplants are safe between people with HIV, US study shows
Study looked at 198 kidney transplants, found similar results whether donated organ came from person with or without AIDS ...
Crain's Detroit5d
Magic Johnson invests in HIV pharmacy startup
NBA Hall of Famer Earvin “Magic” Johnson is investing in a pharmacy startup that helps clinics with high volumes of HIV ...
Medscape6d
HIV-Positive Donors Safe for Kidney Transplants
The availability of such kidney transplants outside of the research setting could substantially improve organ availability ...